DOCSLIB.ORG

Bristol-Myers Squibb Company – Product Pipeline Review – 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bristol-Myers Squibb Company – Product Pipeline Review – 2014 Bristol-Myers Squibb Company – Product Pipeline Review – 2014 Reference Code: GMDHC05245CDB Publication Date: JUN 2014 Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Bristol-Myers Squibb Company – Product Pipeline Review Table of Contents Table of Contents ....................................................................................................................................................................... 2 List of Tables ....................................................................................................................................................................... 12 List of Figures ...................................................................................................................................................................... 12 Bristol-Myers Squibb Company Snapshot.................................................................................................................................. 13 Bristol-Myers Squibb Company Overview ............................................................................................................................. 13 Key Information ................................................................................................................................................................... 13 Key Facts ............................................................................................................................................................................ 13 Bristol-Myers Squibb Company – Research and Development Overview .................................................................................... 14 Key Therapeutic Areas ......................................................................................................................................................... 14 Bristol-Myers Squibb Company – Pipeline Review ..................................................................................................................... 23 Pipeline Products by Stage of Development.......................................................................................................................... 23 Pipeline Products – Monotherapy ......................................................................................................................................... 24 Pipeline Products – Combination Treatment Modalities ......................................................................................................... 25 Pipeline Products – Partnered Products................................................................................................................................ 26 Partnered Products/Combination Treatment Modalities ..................................................................................................... 27 Pipeline Products – Out-Licensed Products .......................................................................................................................... 29 Out-Licensed Products/Combination Treatment Modalities ............................................................................................... 30 Bristol-Myers Squibb Company – Pipeline Products Glance ....................................................................................................... 33 Bristol-Myers Squibb Company – Late Stage Pipeline Products............................................................................................. 33 Pre-Registration Products/Combination Treatment Modalities ........................................................................................... 33 Phase III Products/Combination Treatment Modalities ...................................................................................................... 33 Bristol-Myers Squibb Company – Clinical Stage Pipeline Products ........................................................................................ 34 Phase II Products/Combination Treatment Modalities ....................................................................................................... 34 Phase I Products/Combination Treatment Modalities ........................................................................................................ 37 Bristol-Myers Squibb Company – Early Stage Pipeline Products ........................................................................................... 40 IND/CTA Filed Products/Combination Treatment Modalities .............................................................................................. 40 Preclinical Products/Combination Treatment Modalities .................................................................................................... 41 Discovery Products/Combination Treatment Modalities ..................................................................................................... 43 Bristol-Myers Squibb Company – Drug Profiles ......................................................................................................................... 44 (atazanavir sulfate + cobicistat) ............................................................................................................................................ 44 Product Description ......................................................................................................................................................... 44 Mechanism of Action ....................................................................................................................................................... 44 R&D Progress ................................................................................................................................................................. 44 apixaban ............................................................................................................................................................................. 45 Product Description ......................................................................................................................................................... 45 Mechanism of Action ....................................................................................................................................................... 45 R&D Progress ................................................................................................................................................................. 45 asunaprevir ......................................................................................................................................................................... 46 Product Description ......................................................................................................................................................... 46 Mechanism of Action ....................................................................................................................................................... 46 R&D Progress ................................................................................................................................................................. 46 asunaprevir + daclatasvir ..................................................................................................................................................... 48 Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Bristol-Myers Squibb Company – Product Pipeline Review Product Description ......................................................................................................................................................... 48 Mechanism of Action ....................................................................................................................................................... 48 R&D Progress ................................................................................................................................................................. 48 daclatasvir ........................................................................................................................................................................... 50 Product Description ......................................................................................................................................................... 50 Mechanism of Action ....................................................................................................................................................... 50 R&D Progress ................................................................................................................................................................. 50 (daclatasvir + asunaprevir + beclabuvir) ................................................................................................................................ 52 Product Description ......................................................................................................................................................... 52 Mechanism of Action ....................................................................................................................................................... 52 R&D Progress ................................................................................................................................................................
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
    Review Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions Shilpa Gupta 1,†, David Gill 2,†, Austin Poole 2 and Neeraj Agarwal 2,* 1 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] 2 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; [email protected] (D.G.); [email protected] (A.P.) * Correspondence: [email protected]; Tel.: +1-801-213-5658; Fax: +1-801-585-0124 † These authors contributed equally to this work. Academic Editor: Vita Golubovskaya Received: 14 December 2016; Accepted: 18 January 2017; Published: 27 January 2017 Abstract: Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, there were very limited options for patients who are refractory to chemotherapy, or do not tolerate chemotherapy due to toxicities and overall outcomes have remained very poor. While the role of immunotherapy was first established in non-muscle invasive bladder cancer in the 1970s, no systemic immunotherapy was approved for advanced disease until the recent approval of a programmed death ligand-1 (PD-L1) inhibitor, atezolizumab, in patients with advanced/metastatic UC who have progressed on platinum-containing regimens. This represents a significant milestone in this disease after a void of over 30 years. In addition to atezolizumab, a variety of checkpoint inhibitors have shown a significant activity in advanced/metastatic urothelial carcinoma and are expected to gain Food and Drug Administration (FDA) approval in the near future.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • On the Horizon: Immuno-Oncology (I-O) Combinations
    Immuno-Oncology (I-O) Combinations • Jeffrey A. Sosman, MD • Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Cancer–Immunity Cycle Daniel Chen and Ira Mellman Immunity, Volume 39, Issue 1, 2013, 1 - 10 The Cancer–Immunity Cycle Daniel Chen and Ira Mellman Immunity, Volume 39, Issue 1, 2013, 1 - 10 Stimulatory and Inhibitory Factors in the Cancer-Immunity Cycle Each step of the Cancer-Immunity Cycle requires the coordination of numerous factors, both stimulatory and inhibitory in nature. Stimulatory factors shown in green promote immunity, ... Where will Improvements come from? • Combinations: – Based on Template: anti-PD-1/PD-L1 or with anti-PD- 1/anti-CTLA-4 • Block other co-inhibitory: LAG3, TIM3, KIR, VISTA • Activate co-stimulatory: 4-1BB, OX-40, GITR, CD27, ICOS • Block inhibitory molecules- IDOi, TGFbi, CSF1Ri, anti-IL-6 or anti- IL-10 • Effect trafficking- anti-VEGF, CCL5, CXCR4i • Vaccines- TVEC- oncolytic virus, Neoantigen, other cellular • Adoptive Cellular therapy- TIL, CAR-T cells, TCR T-cells Where will Improvements come from? • Combinations: – Based on Template: anti-PD-1/PD-L1 or with anti-PD- 1/anti-CTLA-4 • Signal Inhibition, BRAF directed (BRAFi+MEKi), MEKi, PI3K inhibition (PTEN effects) • Cytokines- IL-2, IFN a,b,g,, Directed cytokines (FAP-IL-2v or CEA-IL-2v) • Epigenetic modulation- gene expression and EVR expression • Microbiome modification- fecal transplants • Chemotherapy other cytotoxics • Localized Irradiation SBRT, SRS T cells in Tumors Express Multiple Immunoinhibitory Receptors
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • The Evolving Landscape of `Next-Generation' Immune
    European Journal of Cancer 117 (2019) 14e31 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.ejcancer.com Review The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review Luca Mazzarella a, Bruno Achutti Duso a, Dario Trapani a,b, Carmen Belli a, Paolo D’Amico a,b, Emanuela Ferraro a,b, Giulia Viale a,b, Giuseppe Curigliano a,b,* a New Drugs and Early Drug Development for Innovative Therapies Division, IEO, European Institute of Oncology IRCCS, Milan, Italy b University of Milano, Department of Hematology and Hemato-Oncology, Italy Received 17 March 2019; received in revised form 23 April 2019; accepted 26 April 2019 Available online 21 June 2019 KEYWORDS Abstract ‘First-generation’ immune checkpoint inhibitors targeting Cytotoxic T-Lympho- Next generation cyte Antigen 4 (CTLA4) and Programmed death-ligand 1 (PD(L)1) have undoubtedly revolu- immune-checkpoints; tionised the treatment of multiple cancers in the advanced setting. Targeting signalling LAG3; pathways other than core inhibitory modules may strongly impact the outcome of the antitu- TIGIT; mour immune response. Drugs targeting these pathways (‘next-generation’ immune modula- TIM3; tors, NGIMs) constitute a major frontier in translational research and have generated 4-1BB; unprecedented scientific and financial investment. Here, we systematically reviewed published IDO1; literature, abstracts from major cancer conferences and pharma pipelines to identify NGIMs GITR; that have reached clinical development. We identified 107 molecules targeting 16 pathways, Colony stimulating which we classified into 6 groups according to function (inhibitory vs stimulatory) and cell factor-1 (CSF-1) of predominant expression (lymphoid, non-lymphoid and natural killer).
    [Show full text]
  • Immunfarmakológia Immunfarmakológia
    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Study on Stabilization of Human Igg4 Antibodies
    九州大学学術情報リポジトリ Kyushu University Institutional Repository Study on stabilization of human IgG4 antibodies 浪崎, 博史 https://doi.org/10.15017/2534401 出版情報：九州大学, 2019, 博士（創薬科学）, 課程博士 バージョン： 権利関係： ヒト IgG4 抗体の安定化に関する研究 Study on stabilization of human IgG4 antibodies 2019 九州大学 大学院薬学府 臨床薬学部門 細胞生物薬学分野 浪崎 博史 1 略語表 CD; cluster of differentiation Ig; Immunoglobulin CDR; complementary determining region V; variable D; diversity J; joining RAG; recombination-activating gene RSS; recombination signal sequences TdT; terminal deoxynucleotidyl-transferase AID; activation induced cytidine deaminase BCR; B cell receptor TCR; T cell receptor Fab; fragment, antigen binding Fc; Fragment, Crystallizable VH; variable heavy CH; constant heavy VL; variable light CL; constant light CDC; complement-dependent cytotoxicity ADCC; antibody-dependent cellular cytotoxicity ADCP; antibody-dependent cellular phagocytosis NK; natural killer FcγR; Fc gamma receptor ITAM; immunoreceptor tyrosine-based activation motif 2 ITIM; immunoreceptor tyrosine-based inhibitory motif FcRn; neonatal Fc receptor PD-1; programmed cell death 1 PD-L1; programmed cell death –lignd1 VLA4; very late antigen-4 DNP; dinitrophenol ELISA; Enzyme-linked immunosorbent assay KD; dissociation constant SEC; size-exclusion chromatography DSF; differential scanning fluorimetry DSC; differential scanning calorimetry Tm; melting transition RU; resonance unit 3 目次 第一章 序論 p.5 １－１ 背景 p.5 １－１－１ 免疫グロブリンの種類および機能 p.5 １－１－２ 免疫グロブリンの多様性獲得 p.7 １－１－３ ヒト IgG の構造および機能 p.9 １－１－４ 抗体医薬の開発および承認状況 p.13 １－１－５ ヒト IgG4 の抗体医薬の研究開発状況 p.17 １－１－６ ヒト IgG サブクラスにおける安定性 p.21 １－２ 引用文献 p.25 第二章 ヒト IgG4 抗体の低 pH 誘導性凝集体形成における アミノ酸改変による抑制効果に関する研究 p.30 ２－１ 要旨 p.30 ２－２ 研究背景 p.32 ２－３ 材料および方法 p.35 ２－４ 結果 p.43 ２－５ 考察 p.78 ２－６ 引用文献 p.87 謝辞 p.94 4 第一章 序論 １－１ 背景 １－１－１ 免疫グロブリンの種類および機能 免疫グロブリン（Immunoglobulin；Ig）は哺乳細胞に存在する B 細胞から産生される 糖タンパク質であり、外来抗原を認識して結合する機能を有する。Ig は主に血液中 および組織体液中に存在し、細菌やウイルスなどの外来抗原に結合することにより、 白血球またはマクロファージによる食作用、ならびに免疫細胞の結合による免疫作 用により生体防御に関わっている。ヒトの免疫グロブリンは、IgG, IgA, IgM, IgD お よび IgE の 5 つのクラスが存在し (Fig.
    [Show full text]